Category
What It Takes to Launch in 2025: MFN, MFP, IRA, and the New Rules of the Road
Launching a drug in today’s market is all about navigating the right path. With Most Favored Nation (MFN) policies under discussion, Maximum Fair Price (MFP) requirements taking shape, and Inflation Reduction Act (IRA) provisions already impacting revenue models, pharmaceutical manufacturers face a gauntlet of regulatory checkpoints before, during, and after… Read More